Assignee
EXELIXIS INC
US·123 granted patents·143 pending applications·1,935 citations·filing 1998–2025
Top patents by PatentIndex Score
266 records- 0198US10039757B2C-Met modulator pharmaceutical compositionsEXELIXIS INC·Filed 2017·Granted Aug 7, 2018·33 cites·19 claims
- 0298US10034873B2C-met modulator pharmaceutical compositionsEXELIXIS INC·Filed 2017·Granted Jul 31, 2018·33 cites·19 claims
- 0398US7579473B2c-Met modulators and methods of useEXELIXIS INC·Filed 2009·Granted Aug 25, 2009·95 cites·7 claims
- 0498US7265131B2Isoquinolinone derivatives and their use as therapeutic agentsEXELIXIS INC·Filed 2003·Granted Sep 4, 2007·145 cites·27 claims
- 0597US11731941B2Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2022·Granted Aug 22, 2023·8 cites·18 claims
- 0697US11098015B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2021·Granted Aug 24, 2021·9 cites·3 claims
- 0797US11091440B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2021·Granted Aug 17, 2021·8 cites·3 claims
- 0897US11091439B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancerEXELIXIS INC·Filed 2020·Granted Aug 17, 2021·8 cites·5 claims
- 0996US11298349B2Processes for preparing quinoline compounds and pharmaceutical compositions containing such compoundsEXELIXIS INC·Filed 2021·Granted Apr 12, 2022·4 cites·3 claims
- 1096US10548888B2C-Met modulator pharmaceutical compositionsEXELIXIS INC·Filed 2018·Granted Feb 4, 2020·9 cites·19 claims
- 1196US10543206B2Processes for preparing quinoline compounds and pharmaceutical compositions containing such compoundsEXELIXIS INC·Filed 2018·Granted Jan 28, 2020·9 cites·20 claims
- 1296US10123999B2Processes for preparing quinoline compounds and pharmaceutical compositions containing such compoundsEXELIXIS INC·Filed 2016·Granted Nov 13, 2018·9 cites·11 claims
- 1396US7989622B2Phosphatidylinositol 3-kinase inhibitors and methods of their useEXELIXIS INC·Filed 2006·Granted Aug 2, 2011·64 cites·7 claims
- 1496US7803839B2Azetidines as MEK inhibitors for the treatment of proliferative diseasesEXELIXIS INC·Filed 2006·Granted Sep 28, 2010·46 cites·68 claims
- 1595US11724986B2Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2020·Granted Aug 15, 2023·6 cites·4 claims
- 1695US11124482B2C-met modulators and methods of useEXELIXIS INC·Filed 2017·Granted Sep 21, 2021·6 cites·11 claims
- 1795US9809549B2Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancerEXELIXIS INC·Filed 2014·Granted Nov 7, 2017·30 cites·5 claims
- 1895US7999006B2Methods of using MEK inhibitorsEXELIXIS INC·Filed 2007·Granted Aug 16, 2011·51 cites·27 claims
- 1995US7977345B2c-MET modulators and method of useEXELIXIS INC·Filed 2005·Granted Jul 12, 2011·48 cites·3 claims
- 2095US6515109B1Human ECT2 polypeptideEXELIXIS INC·Filed 2001·Granted Feb 4, 2003·179 cites·1 claims
- 2195US6489127B1Methods for identifying anti-cancer drug targetsEXELIXIS INC·Filed 2000·Granted Dec 3, 2002·194 cites·3 claims
- 2294US11433064B2Methods of using c-Met modulatorsEXELIXIS INC·Filed 2020·Granted Sep 6, 2022·6 cites·4 claims
- 2394US10851061B2Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2019·Granted Dec 1, 2020·8 cites·8 claims
- 2494US10159666B2Dosing of cabozantinib formulationsEXELIXIS INC·Filed 2015·Granted Dec 25, 2018·21 cites·8 claims
- 2594US7915250B2Azetidines as MEK inhibitors for the treatment of proliferative diseasesEXELIXIS INC·Filed 2010·Granted Mar 29, 2011·22 cites·26 claims
- 2694US7704995B2Protein kinase modulators and methods of useEXELIXIS INC·Filed 2003·Granted Apr 27, 2010·64 cites·35 claims
- 2794US6703491B1Drosophila sequencesEXELIXIS INC·Filed 1999·Granted Mar 9, 2004·123 cites·18 claims
- 2894US6511824B1Nucleic acids and polypeptides of invertebrate TWIK channels and methods of useEXELIXIS INC·Filed 1999·Granted Jan 28, 2003·195 cites·5 claims
- 2993US10736886B2Methods of using c-Met modulatorsEXELIXIS INC·Filed 2019·Granted Aug 11, 2020·11 cites·6 claims
- 3093US9969692B2Process for preparing quinoline derivativesEXELIXIS INC·Filed 2016·Granted May 15, 2018·21 cites·21 claims
- 3193US9861624B2Method of treating cancerEXELIXIS INC·Filed 2013·Granted Jan 9, 2018·24 cites·3 claims
- 3292US12275706B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2024·Granted Apr 15, 2025·0 cites·6 claims
- 3392US11760726B2Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2021·Granted Sep 19, 2023·2 cites·11 claims
- 3492US11279675B2Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2018·Granted Mar 22, 2022·10 cites·16 claims
- 3592US11123338B2C-met modulator pharmaceutical compositionsEXELIXIS INC·Filed 2019·Granted Sep 21, 2021·2 cites·27 claims
- 3692US10501418B2Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2015·Granted Dec 10, 2019·12 cites·11 claims
- 3792US10273211B2Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideEXELIXIS INC·Filed 2014·Granted Apr 30, 2019·17 cites·2 claims
- 3892US10166225B2Method for treating osteoporosisEXELIXIS INC·Filed 2012·Granted Jan 1, 2019·23 cites·9 claims
- 3992US9365516B2Process for preparing quinoline derivativesEXELIXIS INC·Filed 2012·Granted Jun 14, 2016·27 cites·28 claims
- 4092US7485634B2Azepinoindole and pyridoindole derivatives as pharmaceutical agentsEXELIXIS INC·Filed 2003·Granted Feb 3, 2009·49 cites·100 claims
- 4191US12016854B2Liquid dosage forms to treat cancerEXELIXIS INC·Filed 2022·Granted Jun 25, 2024·1 cites·7 claims
- 4291US11065240B2Drug combinations to treat multiple myelomaEXELIXIS INC·Filed 2015·Granted Jul 20, 2021·6 cites·4 claims
- 4391US8372851B2Pyrazolo pyrimidines as casein kinase II (CK2) modulatorsEXELIXIS INC·Filed 2006·Granted Feb 12, 2013·20 cites·12 claims
- 4491US8362002B2Azetidines as MEK inhibitors for the treatment of proliferative diseasesEXELIXIS INC·Filed 2011·Granted Jan 29, 2013·12 cites·63 claims
- 4591US2025367186A1C-Met Modulator Pharmaceutical CompositionsEXELIXIS INC·Filed 2025·Application pending·0 cites
- 4690US12128039B2Processes for preparing quinoline compounds and pharmaceutical compositions containing such compoundsEXELIXIS INC·Filed 2024·Granted Oct 29, 2024·0 cites·22 claims
- 4790US11141413B2Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioateEXELIXIS INC·Filed 2017·Granted Oct 12, 2021·8 cites·21 claims
- 4890US2025017916A1Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such CompoundsEXELIXIS INC·Filed 2024·Application pending·0 cites
- 4989US2025100966A1Mek inhibitors and methods of their useEXELIXIS INC·Filed 2024·Application pending·0 cites
- 5089US2024156804A1C-Met Modulator Pharmaceutical CompositionsEXELIXIS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 266 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when EXELIXIS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →